Prostate Cancer and Prostatic Diseases最新文献

{"title":"Artificial intelligence may enhance the role of magnetic resonance imaging in prostate cancer focal therapy.","authors":"Ryan C Au, Pocharapong Jenjitranant, Derek W Cool, Jonathan Izawa, Brant Inman, Aaron Ward, Joseph L Chin","doi":"10.1038/s41391-025-00990-9","DOIUrl":"https://doi.org/10.1038/s41391-025-00990-9","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a holistic understanding of Metformin's Role in oncology: responding to methodological limitations and enhancing translational relevance.","authors":"Yuekun Fang, Shengyi Chen, Cheng Bin","doi":"10.1038/s41391-025-00991-8","DOIUrl":"https://doi.org/10.1038/s41391-025-00991-8","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New BPH therapy classification: what really FITs?","authors":"Steven A Kaplan, Dean S Elterman","doi":"10.1038/s41391-025-00985-6","DOIUrl":"https://doi.org/10.1038/s41391-025-00985-6","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abiraterone for \"STAMPEDE-Like\" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?","authors":"Vedang Murthy, Asesh Samanta, Priyamvada Maitre, Prashant Nayak, Pallavi Singh, Archi Agrawal, Amit Joshi, Gagan Prakash","doi":"10.1038/s41391-025-00983-8","DOIUrl":"https://doi.org/10.1038/s41391-025-00983-8","url":null,"abstract":"<p><strong>Purpose: </strong>To assess long-term survival in a \"STAMPEDE-like\" cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term androgen deprivation therapy (LT-ADT) without abiraterone.</p><p><strong>Materials & methods: </strong>Patients with non-metastatic prostate cancer fulfilling \"STAMPEDE high-risk\" criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method.</p><p><strong>Results: </strong>170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS.</p><p><strong>Conclusion: </strong>For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and safety study of the Flostent™ system (RAPID-I).","authors":"Dean Elterman, Ingrid Perscky, Ruben Urena, Alia Codelia-Anjum, Adam Kadlec, Bilal Chughtai","doi":"10.1038/s41391-025-00984-7","DOIUrl":"https://doi.org/10.1038/s41391-025-00984-7","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the feasibility and safety of the FloStent™, a novel nitinol prostatic stent, in men with LUTS secondary to BPH.</p><p><strong>Materials and methods: </strong>This multi-center, single-arm, one-year study included men aged ≥45 with BPH. Participants underwent FloStent™ implantation using a flexible cystoscope. The primary endpoints were device implantability, tolerability, and device retrievability. Secondary assessments included International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), post-void residual (PVR), and adverse events (AEs) at follow-ups over 52 weeks.</p><p><strong>Results: </strong>The study enrolled 15 participants with a mean age of 58.1 years. All attempts at implantation were successful. Postoperative catheterization was not required in any patient. Significant improvements were observed in IPSS and Qmax. Thirteen AEs were reported, all resolved, with no serious complications. Device retrieval was safely performed using standard urological equipment up to one-year post-implantation.</p><p><strong>Conclusions: </strong>This preliminary study indicates that the FloStent™ is a safe and effective treatment option for BPH, providing significant symptom relief and improved urinary function with a favorable risk profile. Further research, including larger, randomized controlled trials, are needed to validate these findings and establish the long-term efficacy and safety of the FloStent™ device.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?","authors":"Cosimo De Nunzio, Riccardo Lombardo, Antonio Cicione, Antonio Franco, Jean-Nicolas Cornu","doi":"10.1038/s41391-025-00986-5","DOIUrl":"https://doi.org/10.1038/s41391-025-00986-5","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study.","authors":"Nikolaos Pyrgidis, Gerald Bastian Schulz, Philipp Weinhold, Michael Atzler, Leo Federico Stadelmeier, Iason Papadopoulos, Christian Stief, Julian Marcon, Patrick Keller","doi":"10.1038/s41391-025-00980-x","DOIUrl":"https://doi.org/10.1038/s41391-025-00980-x","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist on the role of holmium laser enucleation of the prostate (HoLEP), thulium laser enucleation of the prostate (ThuLEP), and transurethral resection of the prostate (TURP) in patients with prostate cancer (PCa). We aimed to analyze their perioperative outcomes and trends.</p><p><strong>Materials and methods: </strong>The German Nationwide Inpatient Data (GRAND) registry was used to identify male patients diagnosed with PCa who underwent HoLEP, ThuLEP, or TURP between 2005 and 2022. Multivariable regression analyses were performed to compare perioperative morbidity and mortality.</p><p><strong>Results: </strong>A total of 221,768 procedures in patients with PCa were performed: 8160 HoLEP, 2285 ThuLEP, and 211,323 TURP. Although TURP remains the predominant technique, the use of HoLEP and ThuLEP has increased significantly in recent years, representing 17% of all cases by 2022. Perioperative outcomes were worse for TURP, with higher transfusion (8.8%) and ICU admission rates (1.7%) compared to HoLEP and ThuLEP (both 2.5% and ≤1.2%, respectively). Postoperative urinary retention and incontinence rates were also lower for laser enucleation techniques than TURP. In patients with PCa undergoing TURP, perioperative outcomes were worse compared to those without PCa, while outcomes for HoLEP and ThuLEP were comparable regardless of PCa status.</p><p><strong>Conclusion: </strong>HoLEP and ThuLEP offer improved perioperative outcomes compared to TURP in patients with PCa.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis.","authors":"Steven Kaplan, Ronald P Kaufman, Dean Elterman, Bilal Chughtai, Claus Roehrborn","doi":"10.1038/s41391-025-00982-9","DOIUrl":"https://doi.org/10.1038/s41391-025-00982-9","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.","authors":"Brian W H Siu, Alex Q Liu, Chi Ho Leung, Steffi K K Yuen, David K W Leung, Chris H M Wong, Ivan C H Ko, Jeremy M H Ho, Ryan W Y Yuen, Henry Y H Meng, Yvonne Y Y Chan, Chi Hang Yee, Jeremy Y C Teoh, Chi Fai Ng, Peter K F Chiu, Lo Ka Lun","doi":"10.1038/s41391-025-00979-4","DOIUrl":"https://doi.org/10.1038/s41391-025-00979-4","url":null,"abstract":"<p><strong>Background: </strong>For transurethral water vapor therapy (Rezūm), the number of water vapor treatment cycles has classically been determined by the prostate length, or the fields of vision (FOV). Apart from treating lower urinary tract symptoms, there is emerging evidence on Rezūm for refractory retention. We aim to investigate the optimal number of treatment cycles for Rezūm in catheter-dependent refractory retention.</p><p><strong>Methods: </strong>From 02/2021 to 09/2023, 168 consecutive catheter-dependent patients undergoing Rezūm at three centres were included in this prospective registry. Treatment Cycles Per Unit Prostate Volume (CPV) was calculated by dividing the number of treatment cycles by the prostate size. After propensity score matching of age and prostate size, 144 patients were analyzed in the CPV ≤ 0.15 and CPV > 0.15 groups in 1:1 ratio. The primary outcome was the International Prostate Symptom Score (IPSS) at 1-year follow-up. Secondary outcomes included catheter removal time, 30-day readmission rates, prostate-specific antigen (PSA) reduction. Logistic regression model and linear mixed model were used.</p><p><strong>Results: </strong>The CPV > 0.15 group demonstrated significantly better IPSS at 1-year follow-up (adjusted mean difference -2.8 points, p = 0.040), and lower 30-day readmission rates (4.2% vs 16.7%, OR 0.22, p = 0.029). Greater PSA reduction was observed in the higher CPV group at 3 months (adjusted mean difference of log-transformed PSA: -0.4 ng/ml, p = 0.022). Median catheter removal times were 14 days (interquartile range 9-29 days) and 15 days (interquartile range 12-40 days) for lower and higher CPV groups respectively (p = 0.059). Six-week IPSS and IPSS-QoL (quality of life score) were similar (p = 0.359 and p = 0.464 respectively).</p><p><strong>Conclusion: </strong>Higher CPV (>0.15) in Rezūm demonstrated superior 1-year IPSS, lower 30-day readmission rates in our matched cohort. A more aggressive treatment approach, contrasting to the standard FOV-based approach, may benefit catheter-dependent patients.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.","authors":"Lequang T Vo, David Armany, Venu Chalasani, Simon V Bariol, Sriskanthan Baskaranathan, Tania Hossack, David Ende, Henry H Woo","doi":"10.1038/s41391-025-00970-z","DOIUrl":"10.1038/s41391-025-00970-z","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic enucleation of the prostate (EEP) has emerged as a leading surgical treatment for benign prostatic hyperplasia (BPH), traditionally managed by transurethral resection of the prostate (TURP). EEP involves complete adenoma removal along the surgical capsule and can be performed using different energy sources, such as holmium, thulium, GreenLight and diode lasers, or bipolar electrocautery. This meta-analysis compares the efficacy and safety of EEP versus TURP.</p><p><strong>Methods: </strong>A comprehensive search of MEDLINE, EMBASE, CENTRAL, Web of Science, and Scopus (2003-present) identified randomised controlled trials (RCTs) comparing EEP with TURP in adult males (≥18 years) with BPH. Primary outcomes comprised functional measures (Qmax, PVR, IPSS, QoL, IIEF-5), while secondary outcomes included adverse events (incontinence, bleeding, infection, re-treatment rates, hospital stay duration). Two reviewers independently performed data extraction and assessed risk of bias using the Cochrane RoB2 tool.</p><p><strong>Results: </strong>Twenty-eight RCTs (n = 3085) met inclusion criteria: 1538 patients underwent EEP and 1547 underwent TURP. EEP was associated with significantly improved IPSS (at 12 months), Qmax (1, 6, 12, 24 months), and PVR (6, 12, 36 months) compared with TURP. Perioperative outcomes favoured EEP, including shorter catheterisation time (MD = -1.12 days), reduced hospital stay (MD = -0.92 days), and lower transfusion rates (RR = 0.22). No significant differences were observed in long-term incontinence or bladder neck contracture, though EEP yielded lower stricture rates (RR = 0.55) and reoperation rates for recurrent BPH (RR = 0.32). Heterogeneity was high in several outcomes, reflecting variability in patient characteristics, enucleation techniques, and surgeon experience.</p><p><strong>Conclusions: </strong>EEP compares favourably with TURP for BPH, providing notable benefits in bleeding control, faster recovery and durable obstruction relief. Anatomical enucleation yields functional outcomes at least equal and often superior to TURP. Energy source choice may reflect resources and surgeon preferences. Future research should distinguish enucleation completeness from energy source.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}